Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 9

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 9
---
 CD20, a clinically validated target on malignant B-cells. Genmab used technology licensed from Medarex Inc. (Medarex) to generate the CD20 antibody forming

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 7/44                   
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
part of epcoritamab. Epcoritamab is marketed as EPKINLY in the U.S., Japan, and other regions, and as TEPKINLY in Europe and other regions. See local prescribing information for specific indications and safety information. In 2020, Genmab entered into a collaboration agreement with AbbVie to jointly develop and commercialize epcoritamab. The companies share commercialization responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

Genmab records sales in the U.S. and Japan and receives tiered royalties between 22% and 26% on remaining global sales outside of these territories, subject to certain royalty reductions. The companies have a broad clinical development program for epcoritamab including five ongoing Phase 3 trials and additional trials in planning. Please consult the U.S. Prescribing Information for EPKINLY and the European Summary of Product Characteristics for TEPKINLY for the labeled indication and safety information.

#### Second Quarter 2025 Updates
• May: Submission of a sBLA to the FDA for SC epcoritamab in combination with R 2 for the treatment of adult patients with relapsed or refractory FL, following at least one prior systemic therapy. The submission is supported by positive topline results from the Phase 3 EPCORE ® FL-1 (NCT05409066) trial.

• June: Results from an analysis of the Phase 1/2 EPCORE NHL-1 study of epcoritamab, including long-term follow-up in adult patients with relapsed/refractory DLBCL who remain in complete response (CR) at two years, were presented at the 2025 ASCO Annual Meeting.

• June: Fourteen abstracts evaluating epcoritamab both as a monotherapy